Concord Drugs

quarterly
yearly
ParticularsMar '22Jun '22Dec '22Mar '23Jun '23
Revenue15.4912.5413.5312.318.98
Expenses15.4112.2912.9112.178.35
EBITDA0.680.981.450.971.46
EBIT0.310.591.070.641.08
Profit Before Tax0.080.260.610.140.63
Net Profit0.030.190.450.160.49
Financial Ratios
Operating Profit Margin7.82%8.67%10.64%7.88%16.26%
Net Profit Margin1.52%1.31%3.33%1.30%5.46%
Earning Per Share (Diluted)0.030.210.520.170.53
Dividends Per Share0.000.000.000.000.00
ⓒ 2016-2023 Groww. All rights reserved, Built with in India
MOST POPULAR ON GROWWVERSION - 4.3.2
STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
MUTUAL FUNDS COMPANIES:  GROWWMF |  SBI |  AXIS |  HDFC |  UTI |  NIPPON INDIA |  ICICI PRUDENTIAL |  TATA |  KOTAK MAHINDRA |  DSP |  CANARA ROBECO |  SUNDARAM |  MIRAE ASSET |  BANDHAN |  FRANKLIN TEMPLETON |  PPFAS |  MOTILAL OSWAL |  INVESCO |  EDELWEISS |  ADITYA BIRLA SUN LIFE |  LIC |  HSBC |  NAVI |  QUANTUM |  UNION |  IDBI |  ITI |  MAHINDRA MANULIFE |  360 ONE |  BOI |  TAURUS |  JM FINANCIAL |  PGIM |  SHRIRAM |  BARODA BNP PARIBAS |  QUANT |  WHITEOAK CAPITAL |  TRUST |  SAMCO |  NJ |  BAJAJ